Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5792621, 8 pages
https://doi.org/10.1155/2017/5792621
Research Article

Sertraline Induces Toxicity and Behavioral Alterations in Planarians

Laboratory of Cellular Neurobiology, Department of Morphological Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Correspondence should be addressed to Marcos Emílio Frizzo; rb.sgrfu@ozzirfsocram

Received 26 December 2016; Revised 26 April 2017; Accepted 4 May 2017; Published 24 May 2017

Academic Editor: Adair Santos

Copyright © 2017 Isabela Salvador Thumé and Marcos Emílio Frizzo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. V. Sheehan and K. Kamijima, “An evidence-based review of the clinical use of sertraline in mood and anxiety disorders,” International Clinical Psychopharmacology, vol. 24, no. 2, pp. 43–60, 2009. View at Publisher · View at Google Scholar
  2. Y. Li, L. Couch, M. Higuchi, J.-L. Fang, and L. Guo, “Mitochondrial dysfunction induced by sertraline, an antidepressant agent,” Toxicological Sciences, vol. 127, no. 2, pp. 582–591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. M. Lee, S. J. Hahn, and B. H. Choi, “Blockade of Kv1.5 channels by the antidepressant drug sertraline,” Korean Journal of Physiology and Pharmacology, vol. 20, no. 2, pp. 193–200, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. B. I. Aldana and M. Sitges, “Sertraline inhibits pre-synaptic Na + channel-mediated responses in hippocampus-isolated nerve endings,” Journal of Neurochemistry, vol. 121, no. 2, pp. 197–205, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kobayashi, K. Washiyama, and K. Ikeda, “Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants,” PLoS ONE, vol. 6, no. 12, Article ID e28208, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. H.-A. Lee, K.-S. Kim, S.-A. Hyun, S.-G. Park, and S. J. Kim, “Wide spectrum of inhibitory effects of sertraline on cardiac ion channels,” Korean Journal of Physiology and Pharmacology, vol. 16, no. 5, pp. 327–332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Ohno, H. Hibino, C. Lossin, A. Inanobe, and Y. Kurachi, “Inhibition of astroglial Kir4.1 channels by selective serotonin reuptake inhibitors,” Brain Research, vol. 1178, no. 1, pp. 44–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. K. Wang, J. Mitchell, and S. Wang, “Block of persistent late na+ currents by antidepressant sertraline and paroxetine,” Journal of Membrane Biology, vol. 222, no. 2, pp. 79–90, 2008. View at Publisher · View at Google Scholar
  9. J.-H. Yeh, T.-K. Sun, C.-T. Chou et al., “Effect of sertraline on Ca2+ fluxes in rabbit corneal epithelial cells,” Chinese Journal of Physiology, vol. 58, no. 2, pp. 85–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. D. O. Rodrigues, I. J. Bristot, F. Klamt, and M. E. Frizzo, “Sertraline reduces glutamate uptake in human platelets,” NeuroToxicology, vol. 51, pp. 192–197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-M. Chien, C.-T. Chou, C.-C. Pan et al., “The mechanism of sertraline-induced [Ca2+]i rise in human OC2 oral cancer cells,” Human and Experimental Toxicology, vol. 30, no. 10, pp. 1635–1643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. K. Huang, H. T. Chang, C. T. Chou et al., “The mechanism of sertraline-induced [Ca2+]i rise in human PC3 prostate cancer cells,” Basic & Clinical Pharmacology & Toxicology, vol. 109, no. 2, pp. 103–110, 2011. View at Publisher · View at Google Scholar
  13. S. Chen, J. Xuan, L. Wan et al., “Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway,” Toxicological Sciences, vol. 137, no. 2, pp. 404–415, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Collados, H. Hallal, and R. J. Andrade, “Sertraline hepatotoxicity: report of a case and review of the literature,” Digestive Diseases and Sciences, vol. 55, no. 6, pp. 1806-1807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Fartoux-Heymann, C. Hézode, E. S. Zafrani, D. Dhumeaux, and A. Mallat, “Acute fatal hepatitis related to sertraline [1],” Journal of Hepatology, vol. 35, no. 5, pp. 683-684, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Persky and J. F. Reinus, “Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity,” Digestive Diseases and Sciences, vol. 48, no. 5, pp. 939–944, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Chen, J. Xuan, L. Couch et al., “Sertraline induces endoplasmic reticulum stress in hepatic cells,” Toxicology, vol. 322, pp. 78–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. C. E. Leonard, W. B. Bilker, C. Newcomb, S. E. Kimmel, and S. Hennessy, “Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia,” Pharmacoepidemiology and Drug Safety, vol. 20, no. 9, pp. 903–913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Lusetti, M. Licata, E. Silingardi, L. Reggiani Bonetti, and C. Palmiere, “Cardiac toxicity in selective serotonin reuptake inhibitor users,” American Journal of Forensic Medicine and Pathology, vol. 36, no. 4, pp. 293–297, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Bérard, J.-P. Zhao, and O. Sheehy, “Sertraline use during pregnancy and the risk of major malformations,” American Journal of Obstetrics and Gynecology, vol. 212, no. 6, pp. 795.e1–795.e12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Fraher, J. M. Hodge, F. M. Collier et al., “Citalopram and sertraline exposure compromises embryonic bone development,” Molecular Psychiatry, vol. 21, no. 5, pp. 656–664, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Hagstrom, O. Cochet-Escartin, S. Zhang, C. Khuu, and E.-M. S. Collins, “Freshwater planarians as an alternative animal model for neurotoxicology,” Toxicological Sciences, vol. 147, no. 1, pp. 270–285, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Hagstrom, O. Cochet-Escartin, and E. S. Collins, “Planarian brain regeneration as a model system for developmental neurotoxicology,” Regeneration, vol. 3, no. 2, pp. 65–77, 2016. View at Publisher · View at Google Scholar
  24. H. B. Sarnat and M. G. Netsky, “The Brain of the Planarian as the Ancestor of the Human Brain,” Canadian Journal of Neurological Sciences, vol. 12, no. 4, pp. 296–302, 1985. View at Publisher · View at Google Scholar · View at Scopus
  25. F. R. Buttarelli, C. Pellicano, and F. E. Pontieri, “Neuropharmacology and behavior in planarians: translations to mammals,” Comparative Biochemistry and Physiology-C Toxicology and Pharmacology, vol. 147, no. 4, pp. 399–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. S. Farrell, K. Gilmore, R. B. Raffa, and E. A. Walker, “Behavioral characterization of serotonergic activation in the flatworm Planaria,” Behavioural Pharmacology, vol. 19, no. 3, pp. 177–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Rawls, H. Shah, G. Ayoub, and R. B. Raffa, “5-HT1A-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planarians,” Neuroscience Letters, vol. 484, no. 2, pp. 113–117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Rawls, T. Thomas, M. Adeola et al., “Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians,” Pharmacology Biochemistry and Behavior, vol. 93, no. 4, pp. 363–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Ramakrishnan and C. Desaer, “Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina,” Pharmacology Biochemistry and Behavior, vol. 99, no. 4, pp. 665–670, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. F. R. Buttarelli, F. E. Pontieri, V. Margotta, and G. Palladini, “Acetylcholine/dopamine interaction in planaria,” Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, vol. 125, no. 2, pp. 225–231, 2000. View at Publisher · View at Google Scholar
  31. F. Passarelli, A. Merante, F. E. Pontieri, V. Margotta, G. Venturini, and G. Palladini, “Opioid-dopamine interaction in planaria: a behavioral study,” Comparative Biochemistry and Physiology-C Pharmacology Toxicology and Endocrinology, vol. 124, no. 1, pp. 51–55, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. R. B. Raffa and P. Desai, “Description and quantification of cocaine withdrawal signs in Planaria,” Brain Research, vol. 1032, no. 1-2, pp. 200–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Palit and N. Ali, “Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 5, pp. 1120–1124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Lajeunesse, C. Gagnon, F. Gagné, S. Louis, P. Čejka, and S. Sauvé, “Distribution of antidepressants and their metabolites in brook trout exposed to municipal wastewaters before and after ozone treatment-Evidence of biological effects,” Chemosphere, vol. 83, no. 4, pp. 564–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Kirchherr and W. N. Kühn-Velten, “Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 843, no. 1, pp. 100–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Saletu, J. Grünberger, and L. Linzmayer, “On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine,” Journal of Neural Transmission, vol. 67, no. 3-4, pp. 241–266, 1986. View at Publisher · View at Google Scholar · View at Scopus
  37. M. C. Mauri, V. Laini, G. Cerveri et al., “Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 26, no. 3, pp. 597–601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Grabicova, R. H. Lindberg, M. Östman et al., “Tissue-specific bioconcentration of antidepressants in fish exposed to effluent from a municipal sewage treatment plant,” Science of the Total Environment, vol. 488-489, no. 1, pp. 46–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. M. Schultz, M. M. Painter, S. E. Bartell et al., “Selective uptake and biological consequences of environmentally relevant antidepressant pharmaceutical exposures on male fathead minnows,” Aquatic Toxicology, vol. 104, no. 1-2, pp. 38–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. L. Willins and H. Y. Meltzer, “Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats,” The Journal of Pharmacology and Experimental Therapeutics, vol. 282, pp. 699–706, 1997. View at Google Scholar
  41. T. Hori, S. Abe, A. Baba, T. Suzuki, and H. Shiraishi, “Effects of repeated phencyclidine treatment on serotonin transporter in rat brain,” Neuroscience Letters, vol. 280, no. 1, pp. 53–56, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. S. P. Vickers, N. Easton, C. S. Malcolm et al., “Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists,” Pharmacology Biochemistry and Behavior, vol. 69, no. 3-4, pp. 643–652, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. K. W. Currie and B. J. Pearson, “Transcription factors lhx1/5-1 and pitx are required for the maintenance and regeneration of serotonergic neurons in planarians,” Development (Cambridge), vol. 140, no. 17, pp. 3577–3588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Bay and A. M. Butt, “Relationship between glial potassium regulation and axon excitability: a role for glial Kir4.1 channels,” GLIA, vol. 60, no. 4, pp. 651–660, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. L. A. Jansen, E. J. Uhlmann, P. B. Crino, D. H. Gutmann, and M. Wong, “Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes,” Epilepsia, vol. 46, no. 12, pp. 1871–1880, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. V. Kucheryavykh, L. Y. Kucheryavykh, C. G. Nichols et al., “Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes,” GLIA, vol. 55, no. 3, pp. 274–281, 2007. View at Publisher · View at Google Scholar · View at Scopus